Safety, Effectiveness and Immunogenicity of heterologous mRNA-1273 Boost
South Africa
Nigel Garrett, Tarylee Reddy, Nonhlanhla Yende-Zuma, Azwidhwi Takalani, Kubashni Woeber, Annie Bodenstein, Phumeza Jonas, Imke Engelbrecht, Waasila Jassat, Harry Moultrie, Debbie Bradshaw, Ishen Seocharan, Jackline Odhiambo, Kentse Khuto, Simone I. Richardson, Millicent A. Omondi, Rofhiwa Nesamari,
Created on
April 29, 2024
Last modified
April 29, 2024
Page views
24476
Download
2
Documentation in PDF
Metadata
DDI/XML
JSON
- Data files
- SHERPA_Safetydata
drug_immune2 (drug_immune2)
Data file: SHERPA_Safetydata
Overview
Valid:
21
Invalid:
0
Type:
Discrete
Width:
20
Range:
-
Format:
character
Questions and instructions
Categories
| Value | Category | Cases | |
|---|---|---|---|
| Asthavent | 1 |
4.8%
|
|
| Azathioprine | 1 |
4.8%
|
|
| Budesonide | 1 |
4.8%
|
|
| CHLROOQUINE | 1 |
4.8%
|
|
| Chloroquine | 1 |
4.8%
|
|
| Epillium 600mg daily | 1 |
4.8%
|
|
| Ezetrol | 1 |
4.8%
|
|
| Infliximab | 1 |
4.8%
|
|
| Lamotrigine 150mg | 1 |
4.8%
|
|
| Mycophelonate | 1 |
4.8%
|
|
| N/A | 5 |
23.8%
|
|
| Prednisone | 3 |
14.3%
|
|
| Telmisartan | 1 |
4.8%
|
|
| Vitamin D | 1 |
4.8%
|
|
| calciferol | 1 |
4.8%
|
Warning: these figures indicate the number of cases found in the data file. They cannot be interpreted as summary statistics of the population of interest.